

cord injury, hypoxic nerve cell damage from cardiac arrest or neonatal distress, epilepsy, Alzheimer's disease, Huntington's disease, Parkinson's disease, dementia, muscle tension, depression, anxiety, panic, obsessive compulsive or post-traumatic stress disorder, schizophrenia, neuroleptic malignant and Tourette's syndrome, inappropriate ADH secretion by the kidney, cirrhosis, nephrosis, congestive heart failure, hypertension, gut motility (e.g. diarrhoea, spastic colon, gastrointestinal ulcer or sarcoidosis), autoimmune diseases, transplant rejection, squamous cell carcinoma, and pancreatitis, based on the effects of calcium ion on cells. Dwg.0/0

FS CPI
FA AB; GI; DCN
MC CPI: B10-A20; C10-A20; B10-B01B; C10-B01B; B10-B02E; C10-B02E; B10-B02F; C10-B02F; B10-B02G; C10-B02G; B10-B03B; C10-B03B; B10-B04B; C10-B04B; B14-C09; C14-C09; B14-E02; C14-E02; B14-E08; C14-E08; B14-E10C; C14-E10C; B14-F01E; C14-F01E; B14-G01; C14-G01; B14-G02D; C14-G02D

L33 ANSWER 20 OF 37 WPINDEX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 1997-161408 [15] WPINDEX Full-text

DNC C1997-051686
TI Treatment of mycotic infections using aminoacid(s) - e.g. for treating deep mycosis, deep dermatomycosis as superficial mycosis.

DC B05 C02 C03
PA (SAKA) OTSUKA PHARM CO LTD; (TAKS) TAKASAGO PERFUMERY CO LTD

CYC 1
PI JP 09030960 A 19970204 (199715)* 6 A61K031-135

ADT JP 09030960 A JP 1995-181654 19950718

PRAI JP 1995-181654 19950718

IC ICM A61K031-135
ICS A61K031-36; A61K031-40; A61K031-415; A61K031-44; A61K031-47

AB JP 09030960 A UPAB: 19970410
Remedy for mycotic infection contains amino cpds. of formula Ph-(CH2)n-NR1R2 or their salts as active ingredient: Ph = phenyl opt. substd. by 1-5 of H, hal, lower alkoxy, trifluoromethyl, amino, di-lower alkylamino, nitro and 1-3C alkylenedioxy, imidazolyl, quinolyl or indolyl; R1 = H or lower alkyl; R2 = 6-C hydrocarbyl opt. substd. by hydroxy; and n = 1 or 2.
USE - The remedy has excellent antifungal activity against e.g. deep mycosis, deep dermatomycosis or superficial mycosis. Dwg.0/0

FS CPI
FA AB; DCN
MC CPI: B06-D01; C06-D01; B06-D02; C06-D02; B10-B01A; C10-B01A; B10-B04A; C10-B04A; B14-A04; C14-A04

L33 ANSWER 21 OF 37 WPINDEX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 1996-333767 [33] WPINDEX Full-text

CR 1996-333936 [33]
DNC C1996-105397
TI New peptide, peptide analog, and aminoacid analog cpds. are protease inhibitors - used to treat neuro-degenerative diseases due to accumulation of amyloid plaques and degeneration of the neuronal cyto-skeleton.

DC B04 B05
IN ALBRECHT, E; MCDONALD, I A; MUNOZ, B; ROWE, B A; SIEGEL, R S; WAGNER, S L
PA (SALK) SALK INST BIOTECHNOLOGY IND ASSOC; (SIBI-N) SIBIA NEUROSCIENCES INC
CYC 70

PI WO 9620725 A2 19960711 (199633)* EN 219 A61K038-55
RW: AT BE CH DE DK EA ES FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG
W: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AU 9646973 A 19960724 (199644) A61K038-55
WO 9620725 A3 19961017 (199649) A61K038-55
US 5714471 A 19980203 (199812) 68 G01N033-53
US 5804560 A 19980908 (199843) A61K038-05
US 5863902 A 19990126 (199911) A61K038-05
US 5872101 A 19990216 (199914) A61K038-05

Best Available Copy